TRCT
TXMD icon

Tower Research Capital (TRC)’s TherapeuticsMD TXMD Stock Holding History

Tower Research Capital (TRC)’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.05K Sell
1,509
-962
-39% -$2.16K ﹤0.01% 4373
2025
Q4 		$4.03K Sell
2,471
-262
-10% -$379 ﹤0.01% 4269
2025
Q3 		$2.94K Sell
2,733
-149
-5% -$167 ﹤0.01% 4563
2025
Q2 		$3.34K Sell
2,882
-2,620
-48% -$3.17K ﹤0.01% 4513
2025
Q1 		$5.09K Buy
5,502
+726
+15% +$723 ﹤0.01% 4161
2024
Q4 		$4.11K Buy
4,776
+2,506
+110% +$3.53K ﹤0.01% 4513
2024
Q3 		$3.77K Sell
2,270
-1,264
-36% -$2.2K ﹤0.01% 4776
2024
Q2 		$5.69K Buy
3,534
+1,897
+116% +$3.83K ﹤0.01% 4661
2024
Q1 		$3.75K Buy
1,637
+1,626
+14,782% +$3.76K ﹤0.01% 4803
2023
Q4 		$25 Sell
11
-928
-99% -$2.24K ﹤0.01% 5810
2023
Q3 		$2.84K Buy
939
+644
+218% +$2.44K ﹤0.01% 5097
2023
Q2 		$1.22K Buy
295
+277
+1,539% +$1.09K ﹤0.01% 5431
2023
Q1 		$0 Buy
+18
New +$86 ﹤0.01% 6282
2022
Q4 		– Sell
-40
Closed – – 6388
2022
Q3 		$0 Sell
40
-160
-80% -$1.3K ﹤0.01% 6501
2022
Q2 		$2K Sell
200
-603
-75% -$5.76K ﹤0.01% 5607
2022
Q1 		$15K Buy
803
+296
+58% +$4.66K ﹤0.01% 3840
2021
Q4 		$9K Buy
507
+285
+128% +$8.54K ﹤0.01% 4729
2021
Q3 		$8K Sell
222
-349
-61% -$15.5K ﹤0.01% 4571
2021
Q2 		$34K Sell
571
-1,204
-68% -$72.9K ﹤0.01% 3364
2021
Q1 		$119K Buy
1,775
+1,050
+145% +$82.2K ﹤0.01% 2458
2020
Q4 		$44K Sell
725
-4,585
-86% -$313K ﹤0.01% 3233
2020
Q3 		$419K Buy
5,310
+4,278
+415% +$341K ﹤0.01% 1874
2020
Q2 		$64K Buy
1,032
+906
+719% +$52.7K ﹤0.01% 2858
2020
Q1 		$7K Buy
126
+40
+47% +$3.97K ﹤0.01% 2194
2019
Q4 		$10K Buy
86
+62
+258% +$8.91K ﹤0.01% 2349
2019
Q3 		$4K Sell
24
-284
-92% -$40K ﹤0.01% 3464
2019
Q2 		$40K Buy
308
+175
+132% +$31.4K ﹤0.01% 1746
2019
Q1 		$32K Buy
+133
New +$35.2K ﹤0.01% 2003
2018
Q4 		– Sell
-7
Closed -$2K – 4364
2018
Q3 		$2K Buy
+7
New +$2.15K ﹤0.01% 3480
2017
Q4 		– Sell
-730
Closed -$193K – 4030
2017
Q3 		$193K Buy
730
+590
+421% +$171K 0.02% 801
2017
Q2 		$37K Buy
140
+130
+1,300% +$32.6K ﹤0.01% 902
2017
Q1 		$4K Sell
10
-163
-94% -$50.4K ﹤0.01% 2346
2016
Q4 		$50K Buy
173
+157
+981% +$48.7K 0.01% 1432
2016
Q3 		$6K Sell
16
-86
-84% -$31.4K ﹤0.01% 2447
2016
Q2 		$44K Buy
102
+79
+343% +$32.6K ﹤0.01% 1652
2016
Q1 		$7K Buy
+23
New +$7.85K ﹤0.01% 2414
2015
Q4 		– Sell
-14
Closed -$4K – 5057
2015
Q3 		$4K Sell
14
-47
-77% -$16.7K ﹤0.01% 2984
2015
Q2 		$24K Buy
61
+25
+69% +$8.82K ﹤0.01% 1945
2015
Q1 		$11K Buy
+36
New +$8.79K ﹤0.01% 2719
2014
Q3 		– Sell
-272
Closed -$60K – 4903
2014
Q2 		$60K Buy
+272
New +$60.5K 0.01% 1185
2014
Q1 		– Sell
-29
Closed -$8K – 4938
2013
Q4 		$8K Buy
+29
New +$6.35K ﹤0.01% 3206
2013
Q3 		– Sell
-89
Closed -$13K – 4855
2013
Q2 		$13K Buy
+89
New +$12.2K ﹤0.01% 2139

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s TXMD Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its TherapeuticsMD (TXMD) stake by 39% in Q1 2026, selling an estimated $2.16K and leaving 1,509 shares worth $3.05K. The position accounts for ﹤0.01% of the portfolio, ranked #4373.

Tower Research Capital (TRC) first reported a position in TXMD in Q2 2013 and has held it in 42 quarters since. The position peaked at $419K in Q3 2020. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • Tower Research Capital (TRC) held 1,509 shares of TherapeuticsMD worth $3.05K as of Q1 2026.
  • Tower Research Capital (TRC) sold 962 TherapeuticsMD shares in Q1 2026, an estimated $2.16K.
  • TherapeuticsMD made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4373 holding.
  • Tower Research Capital (TRC) first reported a position in TherapeuticsMD in Q2 2013 and has held it in 42 quarters since.
  • Tower Research Capital (TRC)'s TherapeuticsMD position peaked at $419K in Q3 2020.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.